Svacina, Martin K. R., Meissner, Anika, Schweitzer, Finja, Ladwig, Anne, Sprenger-Svacina, Alina, Klein, Ines, Wuestenberg, Hauke, Kohle, Felix ORCID: 0000-0002-4429-0367, Schneider, Christian, Grether, Nicolai B., Wunderlich, Gilbert, Fink, Gereon R. ORCID: 0000-0002-8230-1856, Klein, Florian ORCID: 0000-0003-1376-1792, Di Cristanziano, Veronica and Lehmann, Helmar C. (2022). Antibody response after COVID-19 vaccination in intravenous immunoglobulin-treated immune neuropathies. Eur. J. Neurol., 29 (11). S. 3380 - 3389. HOBOKEN: WILEY. ISSN 1468-1331

Full text not available from this repository.

Abstract

Background and purpose This study assessed the prevalence of anti-SARS-CoV-2 antibodies in therapeutic immunoglobulin and their impact on serological response to COVID-19 mRNA vaccine in patients with intravenous immunoglobulin (IVIg)-treated chronic immune neuropathies. Methods Forty-six samples of different brands or lots of IVIg or subcutaneous IgG were analyzed for anti-SARS-CoV-2 IgG using enzyme-linked immunosorbent assay and chemiluminescent microparticle immunoassay. Blood sera from 16 patients with immune neuropathies were prospectively analyzed for anti-SARS-CoV-2 IgA, IgG, and IgM before and 1 week after IVIg infusion subsequent to consecutive COVID-19 mRNA vaccine doses and after 12 weeks. These were compared to 42 healthy subjects. Results Twenty-four (52%) therapeutic immunoglobulin samples contained anti-SARS-CoV-2 IgG. All patients with immune neuropathies (mean age = 65 +/- 16 years, 25% female) were positive for anti-SARS-CoV-2 IgG after COVID-19 vaccination. Anti-SARS-CoV-2 IgA titers significantly decreased 12-14 weeks after vaccination (p = 0.02), whereas IgG titers remained stable (p = 0.2). IVIg did not significantly reduce intraindividual anti-SARS-CoV-2 IgA/IgG serum titers in immune neuropathies (p = 0.69). IVIg-derived anti-SARS-CoV-2 IgG did not alter serum anti-SARS-CoV-2 IgG decrease after IVIg administration (p = 0.67). Conclusions Our study indicates that IVIg does not impair the antibody response to COVID-19 mRNA vaccine in a short-term observation, when administered a minimum of 2 weeks after each vaccine dose. The infusion of current IVIg preparations that contain anti-SARS-CoV-2 IgG does not significantly alter serum anti-SARS-CoV-2 IgG titers.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Svacina, Martin K. R.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Meissner, AnikaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schweitzer, FinjaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ladwig, AnneUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Sprenger-Svacina, AlinaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Klein, InesUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wuestenberg, HaukeUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kohle, FelixUNSPECIFIEDorcid.org/0000-0002-4429-0367UNSPECIFIED
Schneider, ChristianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Grether, Nicolai B.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wunderlich, GilbertUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fink, Gereon R.UNSPECIFIEDorcid.org/0000-0002-8230-1856UNSPECIFIED
Klein, FlorianUNSPECIFIEDorcid.org/0000-0003-1376-1792UNSPECIFIED
Di Cristanziano, VeronicaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Lehmann, Helmar C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-680913
DOI: 10.1111/ene.15508
Journal or Publication Title: Eur. J. Neurol.
Volume: 29
Number: 11
Page Range: S. 3380 - 3389
Date: 2022
Publisher: WILEY
Place of Publication: HOBOKEN
ISSN: 1468-1331
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
DEMYELINATING POLYRADICULONEUROPATHY REPORT; NERVE SOCIETY GUIDELINE; SUBCUTANEOUS IMMUNOGLOBULIN; EXPRESSION; GLOBULIN; EFFICACY; CIDPMultiple languages
Clinical Neurology; NeurosciencesMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/68091

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item